NASDAQ-NMS:BHSE

Coeptis Therapeutics Enters Exclusive License Agreement with University of Pittsburgh for Rights to SNAP-CAR, a "Multi-Antigen" CAR T Technology

Retrieved on: 
Wednesday, September 21, 2022
Securities Exchange Act of 1934, National, Pitt, Surgical oncology, Breast, Engineering, Assistant, Sale, Humanities, Research, Securities Act of 1933, Immunology, Neoplasm, U.S. Securities and Exchange Commission, Name, Division, Antibody, Company, Review, Learning, Therapy, Mouse, Forward-looking statement, Cancer, OTC, Exercise, CEO, Technology, Goal, Lymphatic system, University, Association of American Universities, Security (finance), Association, Proxy, SEC, Prospectus, Hematological Cancer Research Investment and Education Act, CAR, Toxicity, Medical imaging, Vaccine, Pharmaceutical industry, Chemistry

WEXFORD, Pa., Sept. 21, 2022 /PRNewswire/ -- Coeptis Therapeutics, Inc. (OTC PINK: COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announced entry into an exclusive license agreement with the University of Pittsburgh for the rights to a chimeric antigen receptor T cell (CAR T) technology – SNAP-CAR – designed to target multiple antigens simultaneously and potentially address a range of hematologic and solid tumors, including breast and ovarian cancer. Completion of the exclusive license agreement for SNAP-CAR follows Coeptis' entry into an option agreement with the University of Pittsburgh announced in May 2022.

Key Points: 
  • Completion of the exclusive license agreement for SNAP-CAR follows Coeptis' entry into an option agreement with the University of Pittsburgh announced in May 2022.
  • This approach has proven effective in certain cancer types but limits the applicability of those CAR T therapies.
  • SNAP-CAR is designed to be a "universal" CAR T cell therapy platform that can be adapted to different cancer indications.
  • "SNAP-CAR represents a potential breakthrough in CAR T approaches and a significant addition to Coeptis' expanding cell therapy product portfolio," said Dave Mehalick, President and CEO of Coeptis Therapeutics.

LEGENDARY GLOBAL FOOTBALL STAR RONALDINHO JOINS EXPANSION TEAM OWNERSHIP GROUP IN MAJOR ARENA SOCCER LEAGUE

Retrieved on: 
Friday, May 6, 2022
Cosmos, Investment, New York Cosmos (2010), United Nations Office on Sport for Development and Peace, Major Arena Soccer League, Pel, Development, Goodwill ambassador, Michael Striar, FIFA, Time, League, Happiness, Goodwill, United Nations, Association, Sport, Ronaldinho, Life, Goal, Ownership, Growth, MASL

NEW YORK, May 6, 2022 /PRNewswire/ -- Major Arena Soccer League today announced that Brazilian global football legend Ronaldo de Assis Moreira, affectionately known as Ronaldinho Gacho or simply Ronaldinho, is joining the world's best indoor league as a Co-Owner of an expansion team.

Key Points: 
  • NEW YORK, May 6, 2022 /PRNewswire/ -- Major Arena Soccer League today announced that Brazilian global football legend Ronaldo de Assis Moreira, affectionately known as Ronaldinho Gacho or simply Ronaldinho, is joining the world's best indoor league as a Co-Owner of an expansion team.
  • The soccer icon brings worldwide attention to the Major Arena Soccer League, as his ownership reflects his love of the indoor game and pays tribute to his roots in futsal.
  • Major Arena Soccer League is considered by many to be one of the most exciting styles of soccer and play.
  • Ronaldinho's passion for the Arena game and his involvement confirms the upward trajectory of Major Arena Soccer League and its growth.

Coeptis Therapeutics, Inc. and Bull Horn Holdings Corp. Announce Merger Agreement

Retrieved on: 
Tuesday, April 19, 2022
Board, LLP, Chronic lymphocytic leukemia, U.S. Securities and Exchange Commission, Director, Security (finance), Board of directors, Proxy, Virgin Islands, Private Securities Litigation Reform Act, Sale, OTC, Patient, Goal, Multiple myeloma, Person, Karolinska Institute, Review, SPAC, Technology, Prospectus, Nasdaq, Company, Neutralizing antibody, SEC, Registration statement, Forward-looking statement, Register, Kleffman v. Vonage Holdings Corp., NK, Name, Mab, Cancer, Securities Act of 1933, Acquisition, Acute myeloid leukemia, COEP, Therapy, Bull horn acacia, Megaphone

WEXFORD, Pa., and MIAMI, Fla., April 19, 2022 /PRNewswire/ -- Coeptis Therapeutics, Inc. (OTC PINK: COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, and Bull Horn Holdings Corp. (Nasdaq: BHSE) ("Bull Horn"), a special purpose acquisition company (SPAC), today announced they have entered into a definitive merger agreement for a business combination that will result in Coeptis becoming a wholly-owned subsidiary of Bull Horn. Under the terms of the merger agreement, a wholly-owned subsidiary of Bull Horn will merge with and into Coeptis and the holders of the outstanding Coeptis shares will receive equity in Bull Horn valued at $175 million (subject to adjustments). The Boards of Directors of both Coeptis and Bull Horn have unanimously approved the proposed merger, which is subject to customary closing conditions, including receipt of all regulatory approvals, as well as the approval of the proposed merger by Coeptis' and Bull Horn's shareholders. The close of the transaction is anticipated to occur in the third quarter 2022, with Bull Horn to domesticate from the British Virgin Islands to a Delaware corporation prior to the closing. Bull Horn will be rebranded and operate as Coeptis Therapeutics Holdings, Inc. and is expected to list on Nasdaq under the ticker symbol "COEP." Coeptis Therapeutics' current President and Chief Executive Officer, David Mehalick, will lead the combined company as President and Chief Executive Officer, and current Chief Financial Officer of Bull Horn, Chris Calise, will join the post-closing Board of Directors.

Key Points: 
  • Under the terms of the merger agreement, a wholly-owned subsidiary of Bull Horn will merge with and into Coeptis and the holders of the outstanding Coeptis shares will receive equity in Bull Horn valued at $175 million (subject to adjustments).
  • The Boards of Directors of both Coeptis and Bull Horn have unanimously approved the proposed merger, which is subject to customary closing conditions, including receipt of all regulatory approvals, as well as the approval of the proposed merger by Coeptis' and Bull Horn's shareholders.
  • Bull Horn will be rebranded and operate as Coeptis Therapeutics Holdings, Inc. and is expected to list on Nasdaq under the ticker symbol "COEP."
  • Bull Horn, Coeptis and their respective directors, executive officers, other members of management and employees may be deemed participants in the solicitation of proxies from Bull Horn's and Coeptis' stockholders with respect to the proposed business combination.